Research output per year
Research output per year
Search results
-
2023
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy
Vihinen, H., Jokinen, A., Laajala, T. D., Wahid, N., Peltola, L., Kettunen, T., Ronka, A., Tiainen, L., Skytta, T., Kohtamäki, L., Tulokas, S., Karhapää, H., Hernberg, M., Silvoniemi, M. & Mattila, K. E., Jun 2023, In: Clinical Lung Cancer. 24, 4, p. 295-304 10 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2022
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor
Mattila, K. E., Makela, S., Kytölä, S., Andersson, E., Vihinen, P., Ramadan, S., Skyttä, T., Tiainen, L., Vuoristo, M.-S., Tyynela-Korhonen, K., Koivunen, J., Kohtamäki, L., Aittomäki, K. & Hernberg, M., 3 Oct 2022, In: Acta Oncologica. 61, 10, p. 1263-1267 5 p.Research output: Contribution to journal › Article › Scientific › peer-review
-
High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
Kohtamäki, L., Arjama, M., Mäkelä, S., Ianevski, P., Välimäki, K., Juteau, S., Ilmonen, S., Ungureanu, D., Kallioniemi, O., Murumägi, A. & Hernberg, M., Jan 2022, In: Translational oncology. 15, 1, 11 p., 101290.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2021
BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients
Kohtamaki, L. M., Hernberg, M., Jaakkola, M. & Makela, S., Jun 2021, In: Melanoma Research. 31, 3, p. 218-223 6 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018
Tulokas, S. K. A., Kohtamäki, L. M., Mäkelä, S. P., Juteau, S., Albäck, A., Vikatmaa, P. J., Mattila, K. E., Skyttä, T. K., Koivunen, J. P., Tyynelä-Korhonen, K. & Hernberg, M. M., Oct 2021, In: Melanoma Research. 31, 5, p. 456-463 8 p.Research output: Contribution to journal › Article › Scientific › peer-review
-
2020
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Kasanen, H., Hernberg, M., Mäkelä, S., Brück, O., Juteau, S., Kohtamäki, L., Ilander, M., Mustjoki, S. & Kreutzman, A., May 2020, In: Cancer Immunology, Immunotherapy. 69, 5, p. 717-730 14 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Limited-duration anti-PD-1 therapy for patients with metastatic melanoma
Mäkelä, S., Kohtamäki, L., Laukka, M., Juteau, S. & Hernberg, M., 2 Apr 2020, In: Acta Oncologica. 59, 4, p. 438-443 6 p.Research output: Contribution to journal › Article › Scientific › peer-review